Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD).

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4533935)

Published in BMC Infect Dis on August 12, 2015

Authors

David J Templeton1,2,3, Stephen T Wright4, Hamish McManus5, Chris Lawrence6, Darren B Russell7,8,9, Matthew G Law10, Kathy Petoumenos11, Australian HIV Observational Database

Author Affiliations

1: The Kirby Institute, UNSW Australia, Sydney, NSW, 2052, Australia. david.templeton@sswahs.nsw.gov.au.
2: RPA Sexual Health, Sydney Local Health District, Camperdown, NSW, 2050, Australia. david.templeton@sswahs.nsw.gov.au.
3: Central Clinical School, The University of Sydney, Sydney, NSW, 2006, Australia. david.templeton@sswahs.nsw.gov.au.
4: The Kirby Institute, UNSW Australia, Sydney, NSW, 2052, Australia. swright@kirby.unsw.edu.au.
5: The Kirby Institute, UNSW Australia, Sydney, NSW, 2052, Australia. hmcmanus@kirby.unsw.edu.au.
6: The George Institute for Global Health, Level 10, King George V Building, 83-117 Missenden Rd, Camperdown, NSW, 2050, Australia. chrislawrence80@hotmail.com.
7: Cairns Sexual Health Service, PO Box 902, Cairns, QLD 4870, Australia. Darren.russell@health.qld.gov.au.
8: The University of Melbourne, VIC, Australia. Darren.russell@health.qld.gov.au.
9: James Cook University, Queensland, Australia. Darren.russell@health.qld.gov.au.
10: The Kirby Institute, UNSW Australia, Sydney, NSW, 2052, Australia. mlaw@kirby.unsw.edu.au.
11: The Kirby Institute, UNSW Australia, Sydney, NSW, 2052, Australia. kpetoumenos@kirby.unsw.edu.au.

Articles cited by this

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis (2004) 2.74

Racial disparities in HIV virologic failure: do missed visits matter? J Acquir Immune Defic Syndr (2009) 2.58

Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med (2002) 2.02

Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother (2005) 1.67

The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology (2011) 1.59

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients. HIV Clin Trials (2009) 1.42

Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy. PLoS One (2012) 1.14

Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. HIV Med (2009) 1.09

The association of clinical follow-up intervals in HIV-infected persons with viral suppression on subsequent viral suppression. AIDS Patient Care STDS (2013) 1.02

Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region. PLoS One (2013) 0.95

Beyond virological suppression: the role of adherence in the late HAART era. Antivir Ther (2012) 0.93

Loss to follow-up in the Australian HIV Observational Database. Antivir Ther (2014) 0.89

Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml. Antivir Ther (2014) 0.89

HIV diagnoses in indigenous peoples: comparison of Australia, Canada and New Zealand. Int Health (2011) 0.85

The role of T cells in the development of cardiovascular disease in HIV-infected patients. Atherosclerosis (2014) 0.83

HIV and AIDS in aboriginal and Torres Strait Islander Australians: 1992-1998. The National HIV Surveillance Committee. Med J Aust (2000) 0.79

Perinatal HIV transmission and pregnancy outcomes in indigenous women in Western Australia. Aust N Z J Obstet Gynaecol (2007) 0.79

Guarding against an HIV epidemic within an Aboriginal community and cultural framework; lessons from NSW. N S W Public Health Bull (2010) 0.78

Articles by these authors

Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med (2002) 2.02

HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med (2003) 1.52

AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS (2009) 1.17

Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy. PLoS One (2012) 1.14

The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV observational database. J Clin Virol (2003) 1.13

Risk factors and causes of death in the Australian HIV Observational Database. Sex Health (2006) 1.07

Hospitalizations in a cohort of HIV patients in Australia, 1999-2007. AIDS (2010) 0.93

Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Med (2012) 0.93

Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression. J Acquir Immune Defic Syndr (2009) 0.92

Determinants of suicide and accidental or violent death in the Australian HIV Observational Database. PLoS One (2014) 0.90

Loss to follow-up in the Australian HIV Observational Database. Antivir Ther (2014) 0.89

CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts. J Acquir Immune Defic Syndr (2011) 0.87

Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database. HIV Med (2005) 0.83

Recent trends in early stage response to combination antiretroviral therapy in Australia. Antivir Ther (2014) 0.79

Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in Australia. J Int AIDS Soc (2015) 0.78

CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy. Antivir Ther (2017) 0.75